Talus Biosciences, a Seattle, WA-based drug discovery firm, raised $11.2M in Seed+ funding.
The spherical was led by Two Bear Capital, with participation from WRF Capital, NFX, YC Continuity Fund, Funders Membership VC, and BoxOne Ventures.
The corporate intends to make use of the funds to advance its therapeutic applications, which embrace Brachyury-driven cancers and an undruggable transcription issue implicated in prostate most cancers. It’s going to additionally speed up the enlargement of its proprietary multiplexed assays for the rational modulation of transcription components (MARMOT) platform.
Based in 2020 by Alex Federation, PhD, and Lindsay Pino, PhD, Talus Bio is a drug discovery and improvement firm targeted on therapeutics that concentrate on beforehand undruggable transcription components. Its proprietary therapeutics discovery platform, MARMOT (Multiplexed Assays for the Rational Modulation Of Transcription Elements), integrates AI, proteomics, artificial chemistry, and computational biology to engineer and interrogate medicine, proteins, and genomics at scale.
MARMOT leverages new AI fashions educated on Talus Bio’s dataset for transcription issue exercise, to permit scientists to quickly establish optimum candidates from billions of compounds, changing high-throughput screens. With MARMOT, machine studying fashions uncover and optimize modulators for any given transcription issue goal, enabling the large acceleration of discovery screening in reside, unmodified human cells the place targets fold and performance correctly.
FinSMEs
20/08/2024
